Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Study of the Efficacy and the Safety of First Line Treatment With CHOP Plus Rituximab (R-CHOP) in Patients Aged 60 to 80 Years With Previously Untreated T-cell Angioimmunoblastic Lymphoma (AIL).

Authors not listed

Lymphoma Study Association · 2005

Abstract

To evaluate the efficacy and the safety of a front-line treatment combining CHOP regimen and rituximab in patients aged 60 to 80 years with previously untreated AIL.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-07 MST

Cite this

APA
Anonymous. (2005). Study of the Efficacy and the Safety of First Line Treatment With CHOP Plus Rituximab (R-CHOP) in Patients Aged 60 to 80 Years With Previously Untreated T-cell Angioimmunoblastic Lymphoma (AIL). <em>Lymphoma Study Association</em>. https://clinicaltrials.gov/study/NCT00169156
Vancouver
Anonymous. Study of the Efficacy and the Safety of First Line Treatment With CHOP Plus Rituximab (R-CHOP) in Patients Aged 60 to 80 Years With Previously Untreated T-cell Angioimmunoblastic Lymphoma (AIL). Lymphoma Study Association. 2005.
BibTeX
@misc{anon2005Studyo, title = {Study of the Efficacy and the Safety of First Line Treatment With CHOP Plus Rituximab (R-CHOP) in Patients Aged 60 to 80 Years With Previously Untreated T-cell Angioimmunoblastic Lymphoma (AIL).}, author = {Anonymous}, journal = {Lymphoma Study Association}, year = {2005}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings